Randomized, Embedded, Multifactorial Adaptive Platform trial for Communityacquired (REMAP-CAP)
Research payments
$4,206,475
Through program year 2021, $4,206,475 in research payments was reported against Randomized, Embedded, Multifactorial Adaptive Platform trial for Communityacquired (REMAP-CAP), across 16 payments, paid by Amgen Inc..
- Paid by
- Amgen Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $315,275 | 11 |
| 2020 | Research | $3,891,200 | 5 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Derek Angus Pittsburgh, PA Named on 3 payments
- David Huang Pittsburgh, PA Named on 3 payments
- Amanda Pientka Pittsburgh, PA Named on 1 payment
- Stephen Pastores New York, NY Named on 1 payment
- Kent Stock Charleston, SC Named on 1 payment
- Matthew Exline Columbus, NC Named on 1 payment
- Julia Garcia-Diaz New Orleans, LA Named on 1 payment
- Robert Hyzy Ann Arbor, MI Named on 1 payment
- Akram Khan Portland, OR Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.